Trial Profile
A Phase I/IIA Dose-Escalating Trial of BCL-2 Antisense (G3139) [Oblimersen] Treatment for Patients With Androgen-Independent Prostate Cancer or Other Advanced Solid Tumor Malignancies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Oblimersen (Primary) ; Docetaxel
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Jul 2008 New trial record.